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We	report	2	cases	of	pulmonary	Bordetella hinzii infection 
in	immunodeficient	patients.	One	of	these	rare	cases	dem-
onstrated	 the	potential	 transmission	of	 the	bacteria	 from	
an	avian	reservoir	through	occupational	exposure	and	its	
persistence	 in	 humans.	We	 establish	 bacteriologic	man-
agement	of	 these	 infections	and	suggest	 therapeutic	op-
tions	if	needed.
Bordetella hinzii bacteria cause respiratory infections in birds and have been isolated from rodents on rare oc-
casions (1,2). Pulmonary infection, digestive infection, and 
bacteriemia in humans have been reported (3–5). B. hinzii 
can persist for >1 years in the respiratory tract of humans 
(5), but its transmission from birds has not been proven. 
Through 2 new cases and a brief review of the literature, 
we show a possible association between occupational risk 
and pulmonary colonization by B. hinzii. Then, we suggest 
how to manage these infections in humans, although patho-
genicity of this bacterium remains unclear.
Clinical Cases
Case-Patient 1
In April 2013, a 43-year-old man was admitted to the 
Pneumology Service of the University Hospital Centre of 
Rennes (Rennes, France) because of fatigue, fever, and 
exacerbation of bronchiectasis. He had undergone an al-
lograft bone marrow transplantation and therapy with cor-
ticosteroids and chemotherapy for an acute myeloid leu-
kemia diagnosed 15 months earlier but was in remission 
during the infectious episode. After the leukemia was di-
agnosed, he stopped working; his occupation had involved 
cleaning pipes and waste tanks with high-pressure water in 
poultry abattoirs.
The patient was a former smoker with a medical his-
tory of type 1 diabetes, vascular hypertension, and non-
symptomatic chronic bronchiectasis before the allograft. 
He was hospitalized for 2 episodes of pulmonary infec-
tions in October 2012 and February–March 2013, during 
which Escherichia coli was isolated and for which he re-
ceived ciprofloxacin.
On admission, he was febrile (39°C) despite chemo-
prophylaxis with trimethoprim/sulfamethoxazole, posacon-
azole, and valaciclovir. The patient had dyspnea and dry 
cough without sputum production. Physical examination 
found crackles at bases of both lungs. Thoracic radiograph 
showed a cardiomegaly, an interstitial syndrome, and pleu-
ral effusion.
Laboratory analyses showed anemia (hemoglobin 92 
g/L [reference range 130–170 g/L]) and hyperleukcocytosis 
(12.4 G/L [reference range 4–10 G/L]) with 8.3 G/L (ref-
erence range 2–7.5 G/L) polynuclear neutrophils (PNN). 
The inflammatory syndrome was confirmed by the elevat-
ed C-reactive protein concentration (44.7 mg/L [reference 
range <5 mg/L]). Calculated antimicrobial therapy was 
started on the second day after admission with piperacillin/
tazobactam and ciprofloxacin.
Bacteriologic cultures of sputum collected on admis-
sion yielded 109 CFU/mL B. hinzii. Bronchial aspiration 
and bronchoalveolar lavage fluid were collected for micro-
bial investigations 2 days later and showed 107 CFU/mL B. 
hinzii and 3 × 105 CFU/mL Staphylococcus epidermidis, 
respectively. Polymicrobial flora were present in all cul-
tures performed, indicating that those samples were con-
taminated by oropharyngeal flora.
Laboratory analyses for nocardiosis, pneumocystosis, 
aspergillosis, and tuberculosis were negative. Multiplex 
PCR for herpes simplex virus, varicella zoster virus, cy-
tomegalovirus, and Epstein-Barr virus and culture for in-
fluenza viruses A and B, human herpesvirus 6, adenovirus, 
metapneumovirus, and parainfluenza viruses 1–3 did not 
detect any of these viruses.
Because of the persistence of symptoms, the patient’s 
antimicrobial therapy was changed, following a decision 
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after 5 days to target Staphylococcus, to parenteral van-
comycin for 10 days. Clinical improvement of pulmonary 
signs and symptoms was observed after 15 days. In addition, 
physical rehabilitation was initiated to support the malnu-
trition and muscle atrophy. The patient returned home after 
1.5 months of rehabilitation.
Case-Patient 2
In September 2014, a 74-year-old man hospitalized in a 
private clinic for partial laryngectomy and a tracheotomy 
because of a second recurrence of laryngeal cancer was 
transferred to the intensive care unit of the University 
Hospital Center of Bordeaux (Bordeaux, France) for de-
compensation of chronic obstructive pulmonary disease 
11 days later. His medical history included vascular hy-
pertension, dyslipidemia, prostate cancer in 2007 that re-
quired total surgical excision, and ischemic heart disease 
in 2011. He also had chronic obstructive pulmonary dis-
ease that had not been documented or treated and a la-
ryngeal cancer for which he underwent a cordectomy in 
2002 and a partial laryngectomy in 2007. The patient was 
a former airline pilot living in the city; he had not had any 
pets for many years and had had only rare contact with 
poultry during childhood.
On admission, he had fever (38.7°C), respiratory dis-
tress with hypoxemia, and purulent tracheal secretions 
discharging from the tracheotomy orifice. Physical ex-
amination found a high heart rate (107 bpm). Pulmonary 
auscultation was normal. Thoracic radiograph showed sys-
tematic alveolar images on the right. Results of laboratory 
tests revealed anemia (88 g/L [reference range 130–170 
g/L]) and an inflammatory syndrome with hyperleucocy-
tosis (11.8 G/L [reference range 4–10 G/L]) with 11.3 G/L 
(reference range 2–7.5 G/L) PNN.
Tracheal aspiration was performed on admission and 
bronchoalveolar lavage 6 days later and samples were cul-
tured. Tracheal secretions yielded 106 CFU/mL B. hinzii 
and 6 × 107 CFU/mL methicillin-resistant S. aureus. Bron-
choalveolar lavage fluid gave 9 × 102 CFU/mL B. hinzii 
and 102 CFU/mL methicillin-resistant S. aureus. B. hinzii 
was also cultured on ESBL medium (bioMérieux, Marcy 
l’Etoile, France) from a rectal swab sample taken for sys-
tematic research for the carriage of resistant bacteria.
Antimicrobial therapy was started on admission to 
intensive care with piperacillin/tazobactam (7 days) and 
vancomycin (11 days). The patient was transferred after 14 
days, following clinical pulmonary recovery, to the private 
clinic for otorhinolaryngeal care.
Microbiological Investigations
Direct microscopic examination of specimens showed 
substantial presence of PNNs and gram-negative short 
bacilli, except in the bronchoalveolar lavage fluid from 
case-patient 2, in which no bacteria was observed. In both 
case-patients, colonies were apparent after 24 or 48 hours 
of incubation (37°C, 5% CO2) on PolyViteX chocolate 
agar. In case-patient 2, they also grew on trypcase soy agar 
with 5% horse blood and Haemophilus chocolate agar with 
bacitracin (bioMérieux). The colonies were medium sized 
(1–2 mm), smooth, round, convex, and grayish; those from 
case-patient 2 were very mucoid. Microscopic examination 
of colonies showed gram-negative short bacilli. Identifi-
cation was inconclusive with Vitek 2 system IdGN cards 
(bioMérieux) and RapID NH (Remel, Lenexa, KS, USA). 
The Api 20NE strip (bioMérieux) identified B. avium based 
on the score 0000067 with high percentage (96.7%) and 
typicality (T = 1). Routine identification by matrix-assisted 
laser desorption/ionization time-of-flight (MALDI-TOF) 
mass spectrometry (Brucker Daltonik GmbH, Germany) 
gave B. hinzii with good scores (T = 2.29 for case-patient 
1 and T = 2.35 for case-patient 2). Final identification for 
both cases involved amplification and sequencing of 1,480 
nt of 16S rRNA gene, then use of the blastn program (http://
www.ncbi.nlm.nih.gov/BLAST/) and the GenBank data-
base. The nucleotide sequences showed the best BLAST hit 
with B. hinzii (99.9% homology in both cases). Antimicro-
bial susceptibility testing was performed on Mueller-Hin-
ton medium by an Etest method (bioMérieux) and MICs 
determined (Table).
Discussion
B. hinzii is found in the respiratory tract of poultry. Al-
though it was initially described as a commensal bacterium 
in birds, some veterinary isolates appear to have pathogenic 
properties: Register et al. reported that it is associated with 
tracheal lesions in turkeys (1,6). B. hinzii has been sporadi-
cally described in rabbits (6) and rodents (2) and had been 
reported to cause pulmonary disease in laboratory mice (7) 
and bacteremia in rats (2). 
Few cases have been described in humans. Most in-
volved bacteremia or respiratory or digestive infections 
(3–5). B. hinzii was first isolated in 1957 from the sputum 
of a patient in France but was misidentified as Alcaligenes 
faecalis (8). In 1994, Cookson et al. described B. hinzii bac-
teremia in an AIDS patient (4). Two other cases of bactere-
mia in immunodeficient patients were associated with the 
isolation of B. hinzii from the pulmonary tract (9,10).
Two digestive infections have been reported. A fatal 
case was described in an immunocompetent man (11) with 
cholestasis and bacteremia. The second case was a biliary 
infection in a liver transplant recipient: B. hinzii was isolat-
ed from 4 bile samples during a 6-month period (3), dem-
onstrating that colonization by B. hinzii can be long-lasting.
B. hinzii appears as an opportunistic pathogen caus-
ing respiratory infections in cystic fibrosis patients (5,12). 
Other respiratory infections in both immunodeficient and 
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immunocompetent persons have been reported. Gadea et 
al. isolated B. hinzii associated with Nocardia asteroides 
in a bronchoalveolar lavage sample from an AIDS patient 
(13). Palacián Ruiz et al. described a B. hinzii respiratory 
infection in an immunocompetent elderly woman that was 
associated with Klebsiella oxytoca (14). B. hinzii was iso-
lated 8 times during a 1-year period from the respiratory 
tract of a cystic fibrosis patient (5).
B. hinzii infections are presumably underdiagnosed 
because of misidentification by the routine phenotypic 
identification procedures that are the basis for Phoenix 
(Phoenix BD Diagnostic Systems, Sparks, MD, USA) and 
Vitek (bioMérieux) automated systems and for the API 
20NE strip manual system (bioMérieux). Indeed, B. hin-
zii is not referenced in the API 20NE database and often 
gives the same score as B. avium. The API 20NE database 
should be updated and the score 0000067 should be re-
ferred to as B. avium–B. hinzii complex. The mean score 
for 6 clinical isolates analyzed with the MALDI-TOF 
mass spectrometry system (Brucker Daltonik GmbH) by 
the French National Reference Centre of pertussis and 
other bordetelloses was T = 2.31, with T = 2.063 as the 
minimal score. MALDI-TOF is useful to discriminate B. 
hinzii from other Bordetella species (15). Sequencing the 
16S rRNA gene is the most reliable technique to confirm 
the species, but the MALDI-TOF system is more suitable 
for routine identification and would enable more cases 
to be detected.
Although poultry seems to be the major reservoir (1), 
we cannot exclude the possibility that mammals such as 
rabbits and rodents also could be potential reservoirs (2,7). 
Humans can become infected by aerosols from the avian 
reservoir, which probably was the route for case-patient 1, 
who had a pulmonary infection long after exposure. Sur-
vival in the digestive tract is another specificity of B. hinzii 
among the Bordetella species. This bacterial survival was 
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Table. Antimicrobial	drug	susceptibility	testing	for	human	Bordetella hinzii isolates	by	the	Etest	method* 
Antimicrobial	drug 
Case-
patient 1† 
Case-
patient 2† 
BC-306 
(11) 
BC-305 
(11) 
BL-3210 
(3) 
Hristov	et	al. 
isolate	1 (10)‡ 
Hristov	et	al. 
isolate	2 (10)‡ 
Hristov	et	al. 
isolate	3 (10)‡ 
Amoxicillin ND 32 16§ 16§ 12§ ND ND ND 
Amoxicillin–clavulanic	acid ND ND 32 16 ND ND ND ND 
Ampicillin–sulbactam ND ND 16/8 16/8 ND ND ND ND 
Piperacillin 0.38 ND ND ND ND 32 ND ND 
Piperacillin–tazobactam 0.25 0.75 1 1 ND ND ND ND 
Ticarcillin ND ND ND ND ND >32 >64 ND 
Ticarcillin–clavulanic	acid ND 32 32 64 ND ND ND ND 
Cefoxitine ND >256 ND ND ND ND ND ND 
Cefotaxime ND >32 ND ND >32 ND ND ND 
Ceftriaxone ND ND 64 64 ND ND ND >32 
Ceftazidime 1.5 2 4 4 4 ND ND ND 
Cefepime ND 6 8 8 ND >16 >16 >16 
Ertapenem 3 0.023 ND ND ND ND ND ND 
Imipenem 0.75 1.5 2 2 1 ND ND ND 
Meropenem 1 0.125 ND ND ND 1 8 4 
Doripenem 0.5 0.125 ND ND ND ND ND ND 
Aztreonam ND ND ND ND ND >16 >16 ND 
Gentamicin 0.75 4 2 4 4 1 4 2 
Tobramycin 4 48 ND ND ND >8 >8 4 
Amikacin 2 16 ND ND ND 16 4 8 
Clarithromycin 4 ND ND ND ND ND ND ND 
Clindamycin >256 ND ND ND ND ND ND ND 
Rifampin 1 >32 N ND ND ND ND ND 
Levofloxacin >32 0.25 2 2 ND ND ND ND 
Ciprofloxacin >32 0.75 4 4 >32 >2 >2 >2 
Moxifloxacin 4 0.5 ND ND ND ND ND ND 
Cotrimoxazole 0.38 ND 0.047 0.023 ND 0.5/9.5 2/38 ND 
Vancomycin >32 >256 ND ND ND ND ND ND 
Teicoplanin >32 >256 ND ND ND ND ND ND 
Daptomycine >256 >256 ND ND ND ND ND ND 
Linezolid >256 >256 ND ND ND ND ND ND 
Fusidic	acid >32 ND ND ND ND ND ND ND 
Tetracyclin ND ND ND ND 0.38 ND ND ND 
Minocyclin 1 ND ND ND ND 2 >8 ND 
Tigecyclin 0.5 0.38 ND ND ND ND ND ND 
Colistin 0.38 0.094 ND ND ND ND ND ND 
Fosfomycin >1024 >1024 ND ND ND ND ND ND 
*Values	are	MICs	as	determined	by	Etest	in	g/mL	ND,	not	determined.	 
†This study. 
‡Isolates	1,	2,	and	3	of	Hristov	et	al.	case	correspond	to	respiratory	isolates	(1	and	2)	and	blood	isolate	(isolate	3). 
§Ampicillin	rather	than	amoxicillin was	tested. 
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illustrated for case-patient 2, who had a positive culture 
from a rectal swab sample; the bacteria most likely was 
transmitted by the oral route, possibly after ingestion of 
contaminated poultry products (3) or deglutition of respira-
tory secretions.
Several reports have demonstrated the prolonged per-
sistence of B. hinzii in the respiratory and digestive tracts 
(3,5); such persistence, at least in the respiratory tract, is also 
observed for B. petrii and B. bronchiseptica (16). This per-
sistence may explain why infection can develop long after 
exposure and makes identification of the source difficult.
The characteristics of all the reported cases suggest 
that B. hinzii is an opportunistic pathogen in humans. 
Other pathogens were isolated in several cases such that 
the extent of its pathogenicity remains obscure. Surpris-
ingly, Staphylococcus sp. was the most frequently associ-
ated pathogen, raising the possibility of synergy between 
these 2 bacteria (5). The role of B. hinzii is still unclear in 
immunocompetent patients, where it may act as colonizer. 
For case-patient 2, the mucoid aspect of the colonies is 
in accordance with prolonged carriage, as described for 
Pseudomonas aeruginosa (17).
Treatment of nonclassical Bordetella infections is not 
standardized. The interpretation of antimicrobial sensitiv-
ity testing is not established and is usually done by in-
ference from other nonfermentative gram-negative rods. 
According to in vitro sensitivity testing for human isolates 
described in the literature and pharmacology, piperacillin/
tazobactam and carbapenems (excluding ertapenem) may 
be effective (Table). Optimal duration of treatment has 
not been established but should be long enough to cure the 
infection and, if possible, eliminate the bacteria. Both pa-
tients reported here were initially treated with piperacil-
lin/tazobactam without clinical improvement despite the 
sensitivity of the isolates to this association; presumably, 
the treatment duration was too short. The curative doses 
needed to eliminate B. hinzii appear to be high because 
B. hinzii was isolated from case-patient 1 despite prophy-
lactic treatment with trimethoprim/sulfamethoxazole, a 
combination to which the isolate was susceptible. Numer-
ous discrepancies exist between the results of disk diffu-
sion and MIC tests (5), as observed for B. bronchiseptica 
(A. Le Coustumier, unpub. data). MIC testing should be 
performed to confirm the sensitivity of any such isolates. 
We can speculate about possible antimicrobial resistance 
acquisition, regarding fluoroquinolone resistance in case-
patient 1 and his exposure to this pharmacologic class 
during previous hospitalizations, as described elsewhere 
(3), but data remain insufficient to prove it. Microbiologi-
cal tests after the episode are required to evaluate the ef-
fectiveness of treatment.
In conclusion, we report here 2 cases of B. hinzii pul-
monary infection in immunodeficient patients, probably 
after avian exposure. Although the transmission could not 
be clearly established, a potential link exists between the 
occupational exposure and the isolation of B. hinzii in the 
pulmonary tract. The respiratory or digestive carriage can 
be prolonged such that the infection might emerge only 
long after contamination, making identification of the 
source difficult. Although B. hinzii is well established as 
opportunistic, microbiologists and clinicians need to be 
aware of the difficulty in diagnosing infections by this spe-
cies using routine methods. Identification of all clinical 
isolates belonging to nonclassical Bordetella sp. should be 
confirmed by a reference laboratory. Further clinical and 
microbial investigations are necessary to understand the 
epidemiology and the pathogenicity of B. hinzii. Optimal 
antimicrobial treatments need to be established and sup-
ported by pharmacology and antimicrobial in vitro sensi-
tivity testing (bacteriostasis, bactericidy).
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